Related Experiment Videos
Cytomegalovirus and blood transfusion
1North London Blood Transfusion Centre, Edgware, Middlesex, UK.
Blood Reviews
|September 1, 1987
Summary
Transfusion-transmitted cytomegalovirus (CMV) infection poses risks primarily to immunocompromised individuals. Preventing CMV transmission requires careful blood screening and component processing, especially for vulnerable patient groups like infants and transplant recipients.
Area of Science:
- Virology
- Immunology
- Transfusion Medicine
Background:
- Cytomegalovirus (CMV) is a cell-associated herpes virus that can cause primary infections, reactivations, or reinfections.
- Transfusion-transmitted CMV infection is a significant concern primarily for immunocompromised patients, including low birth weight infants and transplant recipients.
- CMV seropositivity varies globally, increasing with age and lower socioeconomic status, necessitating targeted prevention strategies.
Purpose of the Study:
- To highlight the unique challenges of preventing transfusion-transmitted cytomegalovirus (CMV) infections.
- To emphasize the critical need for CMV-free blood products in immunocompromised patient populations.
- To outline strategies for mitigating CMV transmission risks in transfusion medicine.
Main Methods:
- Review of existing literature on transfusion-transmitted CMV infections.
- Analysis of serological studies on CMV prevalence worldwide.
- Discussion of laboratory and administrative efforts in providing CMV-seronegative blood.
- Exploration of prevention methods including leukoreduction, immune globulin administration, and serological screening.
Main Results:
- CMV transmission via transfusion is a concern mainly for immunocompromised patients, where it can lead to severe, potentially fatal complications.
- The virus is primarily transmitted through reactivation of latent infection in white blood cells.
- Effective prevention strategies include leukoreduction (white blood cell removal), washing of blood components, and the use of CMV-seronegative blood products.
- Restriction endonuclease techniques may be used to trace infection origins.
Conclusions:
- Preventing transfusion-transmitted CMV infection is crucial for immunocompromised patients, requiring significant logistical and laboratory resources.
- A multi-faceted approach combining blood product processing and targeted serological screening is essential for patient safety.
- Continued vigilance and optimized strategies are necessary to minimize CMV transmission risks in transfusion medicine.